Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Emerson acquires Glue to bolster AI-driven test and measurement software

Emerson acquires Glue to bolster AI-driven test and measurement software

ReutersReuters2026/08/06 13:03
  • Emerson acquired Glue, adding AI-enabled validation and test software maker behind Glue Studio.
  • Deal targets faster AI-driven test generation and planning across Emerson’s NI Test & Measurement software portfolio.
  • Glue Studio to bolster NI Nigel AI, strengthening workflow connectivity, traceability, and the path from design to verified performance.
  • Transaction terms were not disclosed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emerson Electric Co. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.

Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.

智通财经2026/08/29 03:22
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.